Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Bahleda · SciRah

Researcher profile · Semantic Scholar

R. Bahleda

Share profile

R. Bahleda — researcher profile on SciRah

h-index: 25
Works: 108
Citations: 3,669

Most-cited papers

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
C. Massard, S. Michiels, C. Ferté, M. le Deley +29 more
2017Cancer Discovery667 citations Open access
Semantic Scholar
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
J. Tabernero, R. Bahleda, R. Dienstmann, J. Infante +15 more
2015Journal of Clinical Oncology321 citations
Semantic Scholar
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
R. Bahleda, A. Italiano, C. Hierro, A. Mita +15 more
2019Clinical Cancer Research218 citations Open access
Semantic Scholar
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
F. Bigot, E. Castañón, C. Baldini, A. Hollebecque +14 more
2017European Journal of Cancer217 citations Open access
Semantic Scholar
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
F. Meric-Bernstam, R. Bahleda, C. Hierro, M. Sanson +9 more
2021Cancer Discovery214 citations Open access
Semantic Scholar
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D. Moro-Sibilot, N. Cozic, M. Pérol, J. Mazières +20 more
2019Annals of Oncology188 citations Open access
Semantic Scholar
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
L. Gandhi, R. Bahleda, S. Tolaney, E. Kwak +11 more
2014Journal of Clinical Oncology188 citations
Semantic Scholar
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
J. Soria, F. Debraud, R. Bahleda, B. Adamo +14 more
2014Annals of Oncology178 citations Open access
Semantic Scholar
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
G. Recondo, L. Mezquita, F. Facchinetti, D. Planchard +37 more
2019Clinical Cancer Research156 citations Open access
Semantic Scholar
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.
C. Hénon, J. Blay, C. Massard, O. Mir +6 more
2019Annals of Oncology102 citations Open access
Semantic Scholar
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, E. Nassif, Antoine Italiano, R. Bahleda
2021Frontiers in Immunology90 citations Open access
Semantic Scholar
Facts and new hopes on selective FGFR inhibitors in solid tumors
F. Facchinetti, A. Hollebecque, R. Bahleda, Y. Loriot +3 more
2019Clinical Cancer Research90 citations Open access
Semantic Scholar
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
A. Géraud, T. Hueso, Ariane Laparra, N. Bigé +19 more
2024European Journal of Cancer79 citations
Semantic Scholar
Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors.
F. Meric-Bernstam, H. Arkenau, B. Tran, R. Bahleda +9 more
2018Annals of Oncology72 citations Open access
Semantic Scholar
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
F. Facchinetti, A. Hollebecque, F. Brayé, D. Vasseur +18 more
2023Cancer Discovery60 citations Open access
Semantic Scholar
Targeted therapy-induced radiation recall.
A. Lévy, A. Hollebecque, C. Bourgier, Y. Loriot +7 more
2013European Journal of Cancer60 citations
Semantic Scholar
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
J. Karkera, G. M. Cardona, K. Bell, Dana Gaffney +10 more
2017Molecular Cancer Therapeutics54 citations Open access
Semantic Scholar
Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.
R. Bahleda, R. Dienstmann, B. Adamo, A. Gazzah +11 more
201441 citations
Semantic Scholar
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
C. Sessa, P. LoRusso, A. Tolcher, F. Farace +8 more
2013Clinical Cancer Research41 citations Open access
Semantic Scholar
Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
G. Louvel, R. Bahleda, S. Ammari, C. Le Péchoux +5 more
2018European Respiratory Journal40 citations Open access
Semantic Scholar
Molecular screening for cancer treatment optimization: MOSCATO 01 - A prospective molecular triage trial, interim results
A. Hollebecque, C. Massard, T. de Baére, N. Auger +16 more
201337 citations
Semantic Scholar
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur +16 more
2024Clinical Cancer Research35 citations Open access
Semantic Scholar
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.
H. Herin, S. Aspeslagh, E. Castañón, V. Dyevre +12 more
2018European Journal of Cancer34 citations
Semantic Scholar
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
G. Recondo, L. Mahjoubi, A. Maillard, Y. Loriot +30 more
2020npj Precision Oncology27 citations Open access
Semantic Scholar
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
C. Baldini, F. Danlos, A. Varga, M. Texier +33 more
2022Journal of experimental & clinical cancer research : CR26 citations Open access
Semantic Scholar
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs
C. Hénon, J. Vibert, Thomas Eychenne, N. Gruel +23 more
2024Cell Reports Medicine25 citations Open access
Semantic Scholar
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
C. le Tourneau, Y. Tao, C. Gomez-Roca, V. Cristina +13 more
2020Clinical Cancer Research25 citations
Semantic Scholar
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
R. Bahleda, J. Grilley-Olson, R. Govindan, F. Barlesi +15 more
2017British Journal of Cancer24 citations Open access
Semantic Scholar
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
R. Bahleda, C. Sessa, G. Del Conte, L. Gianni +6 more
2014Investigational new drugs22 citations
Semantic Scholar
Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study
S. Watson, B. Verret, S. Ropert, J. Adam +16 more
2022Cancer Medicine19 citations Open access
Semantic Scholar
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
J. Soria, J. Baselga, N. Hanna, S. Laurie +13 more
2013European Journal of Cancer19 citations
Semantic Scholar
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
P. Martin-Romano, S. Ammari, Yolla El-Dakdoukti, C. Baldini +15 more
2020European Journal of Cancer18 citations
Semantic Scholar
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
J. Soria, J. Strickler, R. Govindan, S. Chai +12 more
201718 citations
Semantic Scholar
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
R. Bahleda, A. Hollebecque, A. Varga, A. Gazzah +8 more
2015British Journal of Cancer17 citations Open access
Semantic Scholar
Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients
C. Ferté, C. Massard, E. Ileana, A. Hollebecque +24 more
201416 citations
Semantic Scholar
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
A. Gazzah, V. Boni, J. Soria, A. Calles +8 more
2018European Journal of Cancer14 citations
Semantic Scholar
Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review
L. Mathiot, C. Baldini, O. Letissier, A. Hollebecque +18 more
2024Current Oncology Reports13 citations
Semantic Scholar
First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.
S. Isakoff, M. Saleh, A. Lugovskoy, S. Mathews +5 more
201413 citations
Semantic Scholar
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
J. Soria, Hui K. Gan, H. Arkenau, Sarah Blagden +15 more
201212 citations
Semantic Scholar
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
P. Grivas, E. Garralda, F. Meric-Bernstam, I. Mellinghoff +37 more
2024Clinical Cancer Research11 citations Open access
Semantic Scholar
Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.
S. Besle, E. Schultz, A. Hollebecque, A. Varga +12 more
2018European Journal of Cancer11 citations
Semantic Scholar
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.
A. Hollebecque, R. Bahleda, L. Faivre, J. Adam +14 more
2017European Journal of Cancer10 citations
Semantic Scholar
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
P. Schöffski, R. Bahleda, Andrew J. Wagner, M. Burgess +6 more
2023Clinical Cancer Research9 citations Open access
Semantic Scholar
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors
R. Bahleda, M. le Deley, Apexa Bernard, S. Chaturvedi +15 more
2018Investigational new drugs9 citations
Semantic Scholar
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
R. Bahleda, A. Varga, Y. Bergé, J. Soria +4 more
2018British Journal of Cancer8 citations Open access
Semantic Scholar
Abstract CT238: TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study
F. Meric-Bernstam, L. Goyal, B. Tran, I. Matos +4 more
2019Clinical Trials7 citations
Semantic Scholar
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
S. Négrier, D. Pérol, R. Bahleda, A. Hollebecque +7 more
2017BMC Cancer7 citations Open access
Semantic Scholar
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial
Robin L. Jones, Roman Groisberg, J. Blay, H. Colman +7 more
2026Nature Communications6 citations Open access
Semantic Scholar
Multi‐omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics
Carine Ngo, Léo Colmet-Daage, J. Vibert, C. Hénon +27 more
2025Cancer Communications6 citations Open access
Semantic Scholar
TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838.
J. Watters, M. Dickson, G. Schwartz, A. Le Cesne +8 more
20156 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Soria×25
Invite
J. Soria — researcher profile on SciRah
A. Hollebecque×22
Invite
A. Hollebecque — researcher profile on SciRah
A. Gazzah×18
Invite
A. Gazzah — researcher profile on SciRah
C. Massard×16
Invite
C. Massard — researcher profile on SciRah

×9

Invite

E. Angevin — researcher profile on SciRah

S. Postel-Vinay×8

Invite

S. Postel-Vinay — researcher profile on SciRah

Invite

A. Varga — researcher profile on SciRah

Invite

V. Ribrag — researcher profile on SciRah

Invite

E. Deutsch — researcher profile on SciRah

A. Marabelle×7

Invite

A. Marabelle — researcher profile on SciRah

Invite

L. Lacroix — researcher profile on SciRah

Invite

Y. Loriot — researcher profile on SciRah